Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine Tablets IP

Description

TELAVINCE EM is a combination antiretroviral therapy (ART) tablet designed for the treatment of HIV-1 infection in adults and adolescents. By combining Tenofovir Disoproxil Fumarate (TDF), Efavirenz, and Emtricitabine, it targets the virus at multiple stages of replication. This single-tablet regimen enhances treatment adherence, reduces pill burden, and effectively suppresses viral load, improving immune system function and overall patient health. Uses and Benefits of TELAVINCE EM TELAVINCE EM is prescribed as part of combination therapy for HIV-1. Its key benefits include: ✅ Effective Viral Suppression: Blocks HIV replication, reducing viral load in the blood. ✅ Boosts Immunity: Helps increase CD4 cell counts, improving immune system function. ✅ Convenient Single-Tablet Regimen: Simplifies therapy, promoting better adherence. ✅ Long-Term Disease Management: Reduces risk of HIV-related complications and progression to AIDS. ✅ Improved Quality of Life: Supports sustained health and daily functionality. How TELAVINCE EM Works The combination of Tenofovir Disoproxil Fumarate, Efavirenz, and Emtricitabine works synergistically to inhibit HIV replication: Tenofovir Disoproxil Fumarate (TDF): A nucleotide reverse transcriptase inhibitor (NRTI) that blocks viral DNA synthesis. Emtricitabine: Another NRTI that prevents HIV from multiplying by interfering with viral reverse transcriptase. Efavirenz: A non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to reverse transcriptase, disrupting viral replication. This multi-targeted approach ensures potent antiviral activity, reduces viral load, and prevents drug resistance when taken consistently under medical supervision. Recommended Dosage Adults and adolescents (≥12 years): Typically one tablet once daily, preferably at bedtime on an empty stomach for optimal absorption. Dosage adjustments may be required for patients with kidney impairment. Always follow the doctor’s prescription and do not discontinue therapy without medical guidance. Side Effects of TELAVINCE EM Common side effects may include: Dizziness, headache, or drowsiness Nausea, vomiting, or diarrhea Fatigue or insomnia Skin rash or mild itching Rare but serious: liver toxicity, severe rash, or psychiatric symptoms Note: Immediate medical attention is advised if severe side effects occur. Precautions and Warnings Avoid use in patients with known hypersensitivity to any component. Monitor liver and kidney function regularly during therapy. Not recommended during pregnancy or breastfeeding unless prescribed by a healthcare provider. Patients with a history of psychiatric disorders should be monitored closely due to potential neuropsychiatric effects of Efavirenz. Do not stop treatment abruptly, as it may lead to viral rebound or resistance. Drug Interactions TELAVINCE EM may interact with: Other antiretroviral medications – dosage adjustments may be required. Certain anticonvulsants, antifungals, or antibiotics – may reduce efficacy. Drugs affecting liver enzymes – may increase Efavirenz blood levels. Always consult your doctor before combining with other medications. Storage Instructions Store at room temperature below 25°C in a dry place. Protect from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date. Why Choose TELAVINCE EM from Steris Healthcare? Steris Healthcare Pvt Ltd is a trusted pharmaceutical company delivering safe, high-quality, and affordable medicines. By choosing TELAVINCE EM, patients benefit from: WHO-GMP Certified Manufacturing: Ensures consistent quality and safety. Effective Combination Therapy: Clinically proven for viral suppression in HIV-1 patients. Improved Safety Profile: Optimized formulation with reduced toxicity risks. Nationwide Accessibility: Available across India with timely delivery. Patient-Centric Support: Guidance and follow-up for safe, effective treatment. FAQs Q1. Can TELAVINCE EM cure HIV? A1. No, TELAVINCE EM suppresses viral replication but does not cure HIV. Lifelong adherence is required to maintain viral suppression. Q2. How long before viral load decreases? A2. Significant reduction in viral load is typically observed within 4–8 weeks of therapy. Q3. Can I take it with food? A3. It is best taken on an empty stomach at bedtime, but follow your doctor’s instructions. Q4. Is TELAVINCE EM safe for long-term use? A4. Yes, with regular monitoring of kidney, liver, and overall health, long-term use is safe and effective. Conclusion: TELAVINCE EM (Tenofovir Disoproxil Fumarate, Efavirenz & Emtricitabine Tablets IP) is a reliable, single-tablet antiretroviral therapy for managing HIV-1 infection. With its potent viral suppression, convenient dosing, and favorable safety profile, it is a trusted choice for patients seeking effective long-term HIV management under medical supervision.